Immuneering公司推进III期Atebimetinib试验,目标为首例一线转移性胰腺癌患者给药,同时获得FDA和EMA的对齐。
Immuneering公司推进III期Atebimetinib试验,目标为首例一线转移性胰腺癌患者给药,同时获得FDA和EMA的对齐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.